Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)

Archived

National Institutes of Health

View on Grants.gov 📝 Build a proposal template ★ Save

Description

The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.

Who can apply

  • Small businesses

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV

Key dates & funding
  • PostedFeb 6, 2020
  • ClosesJan 5, 2022
  • CFDA93.350
Categories
Health

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro